<?xml version="1.0" encoding="iso-8859-1"?>
<rss version="2.0">
	<channel>
	<link>http://salesandmarketingnetwork.com/hsmn_newsfeed_public.rss</link>
	<title>HSMN NewsFeed</title>
	<description><![CDATA[Healthcare Sales & Marketing Network NewsFeed]]></description>
	<lastBuildDate>Thu, 02 Sep 2010 13:51:39 CST</lastBuildDate>
	<language>en-us</language>
	<image>
	<title><![CDATA[The Healthcare Sales & Marketing Network]]></title>
	<width>150</width>
	<height>67</height>
	<link>http://salesandmarketingnetwork.com/news.php</link>
	<url>http://salesandmarketingnetwork.com/images/hsmn_logo_150.gif</url>
	</image>
	<item>
		 <title><![CDATA[ConvaTec Expands AQUACEL(R) Dressing Product Line With Introduction of New Ribbon Dressing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031603</link>
			<pubDate>Thu, 02 Sep 2010 15:37:42 GMT</pubDate>
			<author><![CDATA[ConvaTec]]></author>
		 <description><![CDATA[More Convenient Size is Ideal for Certain Cavity Wounds 

SKILLMAN, N.J., Sept. 2   (HSMN NewsFeed)  -- ConvaTec, a world-leading developer and marketer of innovative medical technologies for community and hospital care, announced today the introduction ... <br/><font color="red">Devices, Wound Care</font><br/><font color="blue">ConvaTec, AQUACEL</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[VA Puget Sound Facilities Standardize with FlexiPort(R) Disposable Cuffs, Reinforcing a Commitment to Patient Safety]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031602</link>
			<pubDate>Thu, 02 Sep 2010 15:34:03 GMT</pubDate>
			<author><![CDATA[Welch Allyn]]></author>
		 <description><![CDATA[Welch Allyn blood pressure cuff technology helps fight infection and lower the cost of health care

SKANEATELES FALLS, N.Y.--(Healthcare Sales & Marketing Network)--Welch Allyn, a leading global manufacturer of frontline medical products and solutions, h... <br/><font color="red">Devices</font><br/><font color="blue">Welch Allyn, FlexiPort, blood pressure cuff, blood pressure</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Long Term Data Presented at ESC 2010 Further Support the Benefit of The CYPHER(R) Sirolimus Drug-Eluting Stent Compared to The ENDEAVOR(R) Zotarolimus-Eluting Stent in Important High-Risk Subgroups]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031601</link>
			<pubDate>Thu, 02 Sep 2010 15:31:09 GMT</pubDate>
			<author><![CDATA[Cordis]]></author>
		 <description><![CDATA[Additional Analysis of 18 Month Data of the SORT OUT III Trial Provides Detail on Safety and Efficacy Outcomes in Patients With Diabetes, Acute Coronary Syndrome, or Treatment of Multiple Lesions

STOCKHOLM, September 2, 2010  (HSMN NewsFeed)  --Three ne... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Cordis, CYPHER, Sirolimus, Drug Eluting Stent, Zotarolimus, Medtronic</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Cardiogenesis Comments on the STAR-Heart Study Presented at European Society of Cardiology (ESC) 2010 Congress]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031600</link>
			<pubDate>Thu, 02 Sep 2010 12:16:06 GMT</pubDate>
			<author><![CDATA[Cardiogenesis]]></author>
		 <description><![CDATA[IRVINE, Calif., Sept. 2  (HSMN NewsFeed)  -- Cardiogenesis Corporation (OTCQB: CGCP), released comments today regarding the STAR-heart study.

The STAR-heart study, which was presented at the European Society of Cardiology 2010 Congress in August 2010, r... <br/><font color="red">Regenerative Medicine, Devices, Cardiology</font><br/><font color="blue">Cardiogenesis, STAR-heart study, stem cell, heart failure, cardiomyopathy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Pfizer to Acquire FoldRx Pharmaceuticals]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031599</link>
			<pubDate>Wed, 01 Sep 2010 13:06:11 GMT</pubDate>
			<author><![CDATA[Pfizer]]></author>
		 <description><![CDATA[FoldRx Focused on First-in-Class, Disease-Modifying, Oral Therapeutics to Treat Diseases Caused by Protein Misfolding

Lead Product Candidate, Tafamidis, in Registration in the European Union as First-in-Class Oral Therapy for Transthyretin Amyloid Polyn... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Pfizer, FoldRx Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[GI Dynamics Announces Distribution Agreement with Elemental Healthcare for the EndoBarrier Gastrointestinal Liner]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031598</link>
			<pubDate>Wed, 01 Sep 2010 13:02:24 GMT</pubDate>
			<author><![CDATA[GI Dynamics]]></author>
		 <description><![CDATA[LEXINGTON, Mass. & HUNGERFORD, England--(Healthcare Sales & Marketing Network)--GI Dynamics, a leader in non-surgical, endoscopic treatments for type 2 diabetes and obesity, today announced it has entered into a new agreement with Elemental Healthcare, bas... <br/><font color="red">Devices, Distribution</font><br/><font color="blue">GI Dynamics, Elemental Healthcare, EndoBarrier</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Celator(R) Pharmaceuticals Raises $20 Million in Series D Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031597</link>
			<pubDate>Wed, 01 Sep 2010 12:59:37 GMT</pubDate>
			<author><![CDATA[Celator Pharmaceuticals]]></author>
		 <description><![CDATA[PRINCETON, N.J., Sept. 1  (HSMN NewsFeed)  -- Celator Pharmaceuticals, a privately held pharmaceutical company developing new and more effective therapies to treat cancer based on the company's proprietary technology, today announced that it raised $20 mil... <br/><font color="red">Biopharmaceuticals, Venture Capital</font><br/><font color="blue">Celator Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[InfraReDx Receives FDA Clearance for LipiScan IVUS Coronary Imaging System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031596</link>
			<pubDate>Wed, 01 Sep 2010 12:56:54 GMT</pubDate>
			<author><![CDATA[InfraReDx]]></author>
		 <description><![CDATA[First Catheter to Combine Near-Infrared Spectroscopy with Intravascular Ultrasound

A Valuable New Tool to Characterize Coronary Plaque and Improve Coronary Stenting

BURLINGTON, Mass., Sept. 1  (HSMN NewsFeed)  -- InfraReDx, Inc., a medical device com... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">InfraReDx, LipiScan,  IVUS Coronary Imaging, intravascular ultrasound</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Archimedes Pharma Receives European Marketing Authorisation for PecFent(R) for the Treatment of Breakthrough Cancer Pain]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031595</link>
			<pubDate>Wed, 01 Sep 2010 12:52:24 GMT</pubDate>
			<author><![CDATA[Archimedes Pharma]]></author>
		 <description><![CDATA[READING, England, September 1, 2010  (HSMN NewsFeed)  -- Archimedes Pharma Ltd., a leading international specialty pharma company, today announced that the European Commission has granted marketing authorisation for its lead product, PecFent*, an innovativ... <br/><font color="red">Biopharmaceuticals, Regulatory</font><br/><font color="blue">Archimedes Pharma, PecFent, fentanyl nasal spray, breakthrough cancer pain</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Inspire Names Robert Savel as Senior Vice President and Chief Technical Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031594</link>
			<pubDate>Wed, 01 Sep 2010 12:48:35 GMT</pubDate>
			<author><![CDATA[Inspire Pharmaceuticals]]></author>
		 <description><![CDATA[DURHAM, N.C.--(Healthcare Sales & Marketing Network)--Inspire Pharmaceuticals, Inc. (NASDAQ: ISPH ) announced today the appointment of Robert M. Savel, II, to the position of Senior Vice President and Chief Technical Officer, effective September 20, 2010. ... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Inspire Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Syneron Appoints New Chief Financial Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031593</link>
			<pubDate>Wed, 01 Sep 2010 12:44:22 GMT</pubDate>
			<author><![CDATA[Syneron Medical]]></author>
		 <description><![CDATA[YOKNEAM, ISRAEL--(Healthcare Sales & Marketing Network) - Syneron Medical Ltd. (NASDAQ:ELOS ), the leading global aesthetic device company, announced today that Asaf Alperovitz has been appointed Chief Financial Officer, effective immediately. Mr. Alperovi... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">Syneron Medical</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Microplasmin Meets Primary Endpoint in Second Phase III Trial in VMA, Confirms Positive Findings of First Trial]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031592</link>
			<pubDate>Wed, 01 Sep 2010 12:38:36 GMT</pubDate>
			<author><![CDATA[ThromboGenics]]></author>
		 <description><![CDATA[Data Presented at ASRS Confirm Previous Phase III Findings and Microplasmin's Potential to Transform the Treatment of Retinal Disorders

 LEUVEN, Belgium, September 1, 2010  (HSMN NewsFeed)  -- ThromboGenics NV (Euronext Brussels: THR), a biopharmaceutic... <br/><font color="red">Biopharmaceuticals, Ophthalmology</font><br/><font color="blue">ThromboGenics, microplasmin, vitreomacular adhesion</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[New 2010 ESC Guidelines for Percutaneous Coronary Interventions Reinforce Importance of FFR in Treatment of Coronary Artery Disease]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031591</link>
			<pubDate>Tue, 31 Aug 2010 22:32:50 GMT</pubDate>
			<author><![CDATA[St. Jude Medical]]></author>
		 <description><![CDATA[FFR is updated to Class 1, level of evidence A, the highest class and level possible; update was driven by the positive results of the landmark FAME trial 

ST. PAUL, Minn.--(Healthcare Sales & Marketing Network)--St. Jude Medical, Inc. (NYSE:STJ ) appla... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">St. Jude Medical, PressureWire, Fractional Flow Reserve</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Allergan, Inc. Receives FDA Approval for LUMIGAN(R) 0.01% as First-Line Therapy Indicated for the Reduction of Elevated Intraocular Pressure in Glaucoma Patients]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031590</link>
			<pubDate>Tue, 31 Aug 2010 22:30:24 GMT</pubDate>
			<author><![CDATA[Allergan]]></author>
		 <description><![CDATA[IRVINE, Calif.--(Healthcare Sales & Marketing Network)--Allergan, Inc. (NYSE:AGN ) today announced the United States Food and Drug Administration (FDA) has approved LUMIGAN&reg; (bimatoprost ophthalmic solution) 0.01% as a first-line therapy indicated for ... <br/><font color="red">Biopharmaceuticals, Ophthalmology, FDA</font><br/><font color="blue">Allergan, LUMIGAN, bimatoprost, intraocular pressure, glaucoma</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Quidel Announces FDA Clearance of Its RapidVue(R) hCG Pregnancy Lateral Flow Diagnostic Test]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031589</link>
			<pubDate>Tue, 31 Aug 2010 22:24:55 GMT</pubDate>
			<author><![CDATA[Quidel]]></author>
		 <description><![CDATA[SAN DIEGO--(Healthcare Sales & Marketing Network)--Quidel Corporation (NASDAQ: QDEL ), a leading provider of rapid diagnostic testing solutions, announced today that it has received 510(k) clearance from the United States Food and Drug Administration (FDA)... <br/><font color="red">Diagnostics, FDA</font><br/><font color="blue">Quidel, RapidVue, hCG, human Chorionic Gonadotropin, pregnancy test</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Dr. Les Paul Joins Caris Life Sciences as Senior Vice President, Medical Affairs]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031588</link>
			<pubDate>Tue, 31 Aug 2010 16:29:58 GMT</pubDate>
			<author><![CDATA[Caris Life Sciences]]></author>
		 <description><![CDATA[Fast-Growing Biosciences Company Forms Medical Affairs Group, Headed by a 30-Year Veteran 

IRVING, Texas, Aug. 31, 2010 --(HSMN NewsFeed) -- Caris Life Sciences(TM), Inc., a leading biosciences company focused on enabling precise and personalized health... <br/><font color="red">Diagnostics, Personnel</font><br/><font color="blue">Caris Life Sciences</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Hill-Rom Appoints Scott Jeffers as Senior Vice President, Global Supply Chain]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031587</link>
			<pubDate>Tue, 31 Aug 2010 16:28:16 GMT</pubDate>
			<author><![CDATA[Hill-Rom]]></author>
		 <description><![CDATA[BATESVILLE, Ind., Aug. 31  (HSMN NewsFeed)  -- Hill-Rom (NYSE:HRC ) today announced the appointment of Scott Jeffers  as Senior Vice President, Global Supply Chain.  Currently serving as General Manager for Global Lean Enterprise at GE Healthcare, Jeffers ... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">Hill-Rom</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Sunshine Heart Announces First Minimally Invasive Thoracotomy Procedures Performed for the C-Pulse(R) Heart Assist System]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031586</link>
			<pubDate>Tue, 31 Aug 2010 16:26:16 GMT</pubDate>
			<author><![CDATA[Sunshine Heart]]></author>
		 <description><![CDATA[Saint Luke's Mid America Heart and Vascular Institute in Kansas City Successfully Implants Innovative Heart Failure Therapy through a Small Incision 

MINNEAPOLIS, MN--(Healthcare Sales & Marketing Network) - Sunshine Heart Inc., a global medical device ... <br/><font color="red">Devices, Cardiology</font><br/><font color="blue">Sunshine Heart,  C-Pulse, Heart Assist, ventricular assist</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Swiss Breast Cancer Patient Becomes First in World to Receive Treatment Using Gated RapidArc from Varian Medical Systems]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031585</link>
			<pubDate>Tue, 31 Aug 2010 16:22:43 GMT</pubDate>
			<author><![CDATA[Varian Medical Systems]]></author>
		 <description><![CDATA[BELLINZONA, Switzerland, Aug. 31  (HSMN NewsFeed)  -- A 51-year-old breast cancer patient from Switzerland  has become the first person in the world to be treated using Gated RapidArc&reg;, which makes it possible to monitor patient breathing and compensat... <br/><font color="red">Devices, Oncology</font><br/><font color="blue">Varian Medical Systems, RapidArc, Gated RapidArc, radiotherapy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Gary O'Hara Named Chief Technology Officer at Sanomedics]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031584</link>
			<pubDate>Tue, 31 Aug 2010 16:20:50 GMT</pubDate>
			<author><![CDATA[Sanomedics]]></author>
		 <description><![CDATA[Co-founded Intelligent Medical Systems

Invented the first commercialized infrared tympanic thermometer (FirstTemp&reg; and Genius&reg; brands)

Co-founded Tryom Inc., creating acclaimed backgammon, chess and contract bridge games

Member of venture ... <br/><font color="red">Devices, Personnel</font><br/><font color="blue">Sanomedics</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[CORDIS Announces Results of Ten-Year CYPHER(R) Sirolimus-Eluting Coronary Stent Follow-Up]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031583</link>
			<pubDate>Tue, 31 Aug 2010 12:21:14 GMT</pubDate>
			<author><![CDATA[Cordis]]></author>
		 <description><![CDATA[The Publication of 10-Year Follow-Up Test Results on the First CYPHER(R) Sirolimus-Eluting Coronary Stent Patient Reveal the Stent's Outstanding Efficacy and Safety

STOCKHOLM, August 31, 2010  (HSMN NewsFeed)  -- Cordis Corporation, a worldwide leader i... <br/><font color="red">Devices, Interventional Cardiology</font><br/><font color="blue">Cordis, CYPHER, drug eluting stent, Sirolimus</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Rivaroxaban Successfully Demonstrated Non-Inferiority Compared to Standard of Care for the Prevention of Recurrent Venous Thromboembolism in Pivotal Phase 3 Study]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031582</link>
			<pubDate>Tue, 31 Aug 2010 12:15:47 GMT</pubDate>
			<author><![CDATA[J&JPRD]]></author>
		 <description><![CDATA[Latest Results from EINSTEIN Program Presented at European Society of Cardiology Congress

STOCKHOLM--(Healthcare Sales & Marketing Network)--Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD), announced today that the investigation... <br/><font color="red">Biopharmaceuticals</font><br/><font color="blue">J&JPRD, Johnson & Johnson, rivaroxaban, venous thromboembolism, DVT</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Meda acquires Alaven, a US specialty pharma company]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031581</link>
			<pubDate>Mon, 30 Aug 2010 13:37:31 GMT</pubDate>
			<author><![CDATA[Meda AB]]></author>
		 <description><![CDATA[Meda acquires Alaven in the US

Consistent step in Meda’s growth strategy
Sales level of about 800 MSEK and profitability on par with Meda’s
Organization of approximately 180 employees
Reinforces Meda as a global specialty pharma company

Meda gains... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Meda AB, Alaven</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Aptus Endosystems Completes $15 Million Series AA Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031580</link>
			<pubDate>Mon, 30 Aug 2010 13:32:13 GMT</pubDate>
			<author><![CDATA[Aptus Endosystems]]></author>
		 <description><![CDATA[Funding will Support Further Clinical Activity for Novel Aortic Aneurysm Treatment

SUNNYVALE, Calif.--(Healthcare Sales & Marketing Network)--Aptus Endosystems, Inc., a medical device company developing advanced technology for endovascular aneurysm repa... <br/><font color="red">Devices, Venture Capital</font><br/><font color="blue">Aptus Endosystems, endovascular aneurysm repair</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Otonomy Closes $38.5 Million Series B Financing]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031579</link>
			<pubDate>Mon, 30 Aug 2010 13:29:58 GMT</pubDate>
			<author><![CDATA[Otonomy]]></author>
		 <description><![CDATA[Strong Investor Syndicate to Fund Otonomy to Become Leading Company in the Development of Locally Delivered Therapeutics for Ear Disorders

SAN DIEGO, Aug. 30  (HSMN NewsFeed)  -- Otonomy, Inc. announced today that it has closed a $38.5 million Series B ... <br/><font color="red">Biopharmaceuticals, Venture Capital</font><br/><font color="blue">Otonomy</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[King Pharmaceuticals Appoints Jeffrey Bailey Chief Commercial Officer]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031578</link>
			<pubDate>Mon, 30 Aug 2010 13:27:21 GMT</pubDate>
			<author><![CDATA[King Pharmaceuticals]]></author>
		 <description><![CDATA[BRISTOL, TN--(Healthcare Sales & Marketing Network) - King Pharmaceuticals, Inc. (NYSE:KG ) announced today the appointment of Jeffrey A. Bailey to the position of Chief Commercial Officer. Mr. Bailey will be responsible for the Company's commercial activi... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">King Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Genzyme Confirms Receipt of Unsolicited Proposal]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031577</link>
			<pubDate>Mon, 30 Aug 2010 13:23:56 GMT</pubDate>
			<author><![CDATA[Genzyme]]></author>
		 <description><![CDATA[CAMBRIDGE, Mass.--(Healthcare Sales & Marketing Network)--Genzyme Corp. (NASDAQ: GENZ ) today confirmed that it has received an unsolicited, non-binding proposal from Sanofi-Aventis to acquire all the outstanding shares of Genzyme for $69 per share in cash... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">Genzyme, Sanofi-Aventis</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Easton Pharmaceuticals Inc. Announces Experienced CFO Appointment to Management Team]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031576</link>
			<pubDate>Mon, 30 Aug 2010 13:19:58 GMT</pubDate>
			<author><![CDATA[Easton Pharmaceuticals]]></author>
		 <description><![CDATA[Lee Hendelson to Join Easton Pharmaceuticals, Public Company Experience Invaluable as New CFO

TORONTO, Aug. 30, 2010 --(HSMN NewsFeed) -- Easton Pharmaceuticals (Pink Sheets:EAPH ), a specialty pharmaceutical company that designs, develops, and markets ... <br/><font color="red">Biopharmaceuticals, Personnel</font><br/><font color="blue">Easton Pharmaceuticals</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[AngioDynamics Expands Its VenaCure EVLTTM System to Offer Physicians Fewer Procedure Steps and a Faster Procedure Time]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031575</link>
			<pubDate>Mon, 30 Aug 2010 13:16:01 GMT</pubDate>
			<author><![CDATA[AngioDynamics]]></author>
		 <description><![CDATA[New Access System Cuts Number of Procedure Steps in Half for Varicose Vein Treatment

ALBANY, N.Y.--(Healthcare Sales & Marketing Network)--AngioDynamics (NASDAQ: ANGO ) announced today the launch of a new access kit allowing fewer procedure steps and fa... <br/><font color="red">Devices</font><br/><font color="blue">AngioDynamics, VenaCure EVLT</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Toshiba Installs 1,000th MR System Worldwide]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031574</link>
			<pubDate>Mon, 30 Aug 2010 13:13:16 GMT</pubDate>
			<author><![CDATA[Toshiba America Medical Systems]]></author>
		 <description><![CDATA[Vantage Atlas’ Patient-Focused Features Ideal for Pediatric Facility

TUSTIN, Calif.--(Healthcare Sales & Marketing Network)--Diagnostic imaging leader Toshiba America Medical Systems, Inc. has installed its 1,000th MR system worldwide. Kosair Children’s... <br/><font color="red">Devices, Radiology</font><br/><font color="blue">Toshiba America Medical Systems</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[EndoGastric Solutions Completes $30 Million Financing Round]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031573</link>
			<pubDate>Mon, 30 Aug 2010 13:10:24 GMT</pubDate>
			<author><![CDATA[EndoGastric Solutions]]></author>
		 <description><![CDATA[Series F Investment Supports Rapid Adoption of NOS Technology

REDWOOD CITY, Calif.--(Healthcare Sales & Marketing Network)--EndoGastric Solutions (EGS), the recognized leader in the emerging field of Natural Orifice Surgery (NOS), today announced that C... <br/><font color="red">Devices, Surgery, Venture Capital</font><br/><font color="blue">EndoGastric Solutions, Natural Orifice Surgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[U.K. Bariatric Surgeon Performs Europe's First ROSE Procedures Using USGI Medical's Incisionless Operating Platform(TM) (IOP)]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031572</link>
			<pubDate>Mon, 30 Aug 2010 13:07:42 GMT</pubDate>
			<author><![CDATA[USGI Medical]]></author>
		 <description><![CDATA[Scar-Free Procedure Designed to Repair Previous Bariatric Surgery; Similar Techniques Will be Used to Reduce Stomach Size in Obese Patients

SAN CLEMENTE, Calif., Aug. 30, 2010 --(HSMN NewsFeed) -- USGI Medical, Inc., the Incisionless Surgery Company, an... <br/><font color="red">Devices, Surgery</font><br/><font color="blue">USGI Medical, Incisionless Surgery, ROSE Procedure</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Teriflunomide Significantly Reduced Annualized Relapse Rate and was Well Tolerated in MS Patients]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031571</link>
			<pubDate>Mon, 30 Aug 2010 13:02:29 GMT</pubDate>
			<author><![CDATA[Sanofi-aventis]]></author>
		 <description><![CDATA[First Results From the TEMSO Phase III Trial to be Presented During the ECTRIMS Congress in October 2010

PARIS, August 30, 2010  (HSMN NewsFeed)  -- Sanofi-aventis (EURONEXT: SAN and NYSE: SNY) announced today that the investigational once-daily oral dr... <br/><font color="red">Biopharmaceuticals, Neurology</font><br/><font color="blue">Sanofi-aventis, multiple sclerosis, teriflunomide, TEMSO trial</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[sanofi-aventis Announces Non-Binding Offer to Acquire Genzyme]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031570</link>
			<pubDate>Mon, 30 Aug 2010 04:00:00 GMT</pubDate>
			<author><![CDATA[sanofi-aventis]]></author>
		 <description><![CDATA[$69 Per Share All-Cash Offer Represents Immediate and Certain Value and a Significant Premium for Genzyme Shareholders

Transaction Would Help Genzyme Achieve its Vision of Making a Positive Impact on the Lives of People with Serious Diseases

Transact... <br/><font color="red">Biopharmaceuticals, Mergers & Acquisitions</font><br/><font color="blue">sanofi-aventis, Genzyme</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Medical Action Industries Inc. Completes Acquisition of AVID Medical, Inc.]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031569</link>
			<pubDate>Fri, 27 Aug 2010 14:58:33 GMT</pubDate>
			<author><![CDATA[Medical Action Industries]]></author>
		 <description><![CDATA[Announces Analyst Call for Friday, 8/27 at 11 a.m. ET

BRENTWOOD, N.Y.--(Healthcare Sales & Marketing Network)--Medical Action Industries Inc. (NASDAQ: MDCI ) announced the acquisition of AVID Medical, Inc., a leading provider of custom procedure trays s... <br/><font color="red">Devices, Mergers & Acquisitions</font><br/><font color="blue">Medical Action Industries, AVID Medical</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Exactech Acquires Minimally Invasive Spine Reconstruction Portfolio]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031568</link>
			<pubDate>Fri, 27 Aug 2010 14:56:05 GMT</pubDate>
			<author><![CDATA[Exactech]]></author>
		 <description><![CDATA[GAINESVILLE, Fla.--(Healthcare Sales & Marketing Network)--Exactech, Inc. (NASDAQ:EXAC), a developer and producer of bone and joint restoration products for hip, knee, shoulder, spine and biologic materials, announced today the acquisition of several innov... <br/><font color="red">Devices, Acquisitions, Orthopaedic, Neurosurgery</font><br/><font color="blue">Exactech, VertiFlex, Silverbolt, Pedicle Screw, spine surgery</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Novartis receives FDA approval of Tekamlo, a single-pill combination of aliskiren and amlodipine to treat high blood pressure]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031567</link>
			<pubDate>Fri, 27 Aug 2010 14:53:25 GMT</pubDate>
			<author><![CDATA[Novartis Pharmaceuticals]]></author>
		 <description><![CDATA[Tekamlo combines in a single-pill the only approved direct renin inhibitor, Tekturna, with the widely prescribed calcium channel blocker, amlodipine

Data showed Tekamlo significantly reduced blood pressure compared to amlodipine or Tekturna alone

Up ... <br/><font color="red">Biopharmaceuticals, Cardiology, FDA</font><br/><font color="blue">Novartis Pharmaceuticals, aliskiren, amlodipine, Tekamlo</font>]]>
			</description>
	</item>
	<item>
		 <title><![CDATA[Genentech Provides Update on FDA Application for T-DM1]]></title>
			<link>http://salesandmarketingnetwork.com/news_release.php?ID=2031566</link>
			<pubDate>Fri, 27 Aug 2010 14:49:11 GMT</pubDate>
			<author><![CDATA[Genentech]]></author>
		 <description><![CDATA[SOUTH SAN FRANCISCO, Calif.--(Healthcare Sales & Marketing Network)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced the U.S. Food and Drug Administration (FDA) issued a Refuse to File letter for accelerated approval fo... <br/><font color="red">Biopharmaceuticals, Oncology, FDA</font><br/><font color="blue">Genentech, Roche Group, trastuzumab-DM1, T-DM1, HER2, armed antibody</font>]]>
			</description>
	</item>
	</channel>
</rss>